Beyond the Standard: Individualized Approaches to Dual Antiplatelet Therapy Gain Attention
Dirk Sibbing, Professor, Cardiologist and Angiologist at Privatklinik Lauterbacher Mühle and LMU Munich, shared an insightful post on LinkedIn:
”When it comes to dual antiplatelet treatment we are still using a non-individualized approach in our everyday clinical practice for patients after PCI.
However, evidence is accumulating that sex, age, BMI and many more variables may constitute relevant treatment effect modifiers for drugs like clopidogrel, prasugrel or ticagrelor.
See the latest data on DAPT and sex in the European Heart Journal and my Editorial that puts the findings into perspective.”
Read the full article here.
Article: Dual antiplatelet therapy modulation strategies beyond standard of care: a promising path towards individualized antiplatelet treatment
Author: Dirk Sibbing
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Feb 20, 2026, 10:26Eithne Sexton: Our Interactive Dashboards for Future Stroke Projections at SPHeRE Conference
-
Feb 20, 2026, 10:06Rémi Bonjean: The 1st VHHs Against Active Rap1 to Monitor Platelet Activation
-
Feb 20, 2026, 09:50Latifa Alhassan: HIV Is a Danger Looming For Our Unborn Children and For The Economy of Ghana
-
Feb 20, 2026, 09:35Gregory Makris: Factor XI Makes the Leap from OCEANIC Stroke to the ESO 2025 Update
-
Feb 20, 2026, 09:27Waseem Mujahed: Compartment Syndrome as the Initial Presentation of Postpartum Acquired Hemophilia
-
Feb 20, 2026, 09:21Piotr Czempik: Viscoelastic Testing Guiding Lumbar Puncture in Waldenström’s Macroglobulinemia
-
Feb 20, 2026, 09:14Edoxaban Versus Dalteparin in Cancer-Associated VTE – JTH
-
Feb 20, 2026, 09:04Rens De Groot: The 1st Reported Case of Caplacizumab Resistance
-
Feb 20, 2026, 08:58Adeniji Mustapha: Advocacy for Health Doesn’t Require a License